Cite
HARVARD Citation
Papp, K. et al. (2019). Efficacy of tildrakizumab for moderate‐to‐severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. Journal of the European Academy of Dermatology and Venereology. pp. 1098-1106. [Online].